Profound Medical Corp.
PROFHealthcareNASDAQMedical Devices · Last scanned Jul 22, 2026
Scan Results
Daily timeframeProfound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. At a $251.1M market cap, Profound Medical Corp. ranks as a micro-cap company within healthcare. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.
Market Cap
$251.1M
Beta
0.53
P/E (TTM)
—
P/E (Fwd)
-9.19
EPS (TTM)
$-1.24
EPS (Fwd)
$-0.75
ROE
-70.6%
ROA
-35.5%
Cash
$50.3M
Total Debt
$7.5M
Free CF
-$22.8M
52W Change
17.7%
Annual Financials
Cash vs Debt
Where PROF stands vs its 150-day and 200-day moving averages
As of the July 7, 2026 close, PROF finished 7.12% above its 150-day moving average ($6.88) and 11.84% above its 200-day moving average ($6.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PROF overbought or oversold?
At the July 7, 2026 close, PROF's RSI(14) was 68.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $50.3M in cash comfortably exceeding the $7.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$22.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -70.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $6.7M (2022) to $16.1M (2025), reflecting a 141% increase over the period.
The relatively low beta of 0.53 suggests PROF is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, PROF has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing PROF's risk profile alongside its fundamentals and technical indicators provides a more complete picture.